Ignite Creation Date:
2024-05-06 @ 7:40 AM
Last Modification Date:
2024-10-26 @ 11:50 AM
Study NCT ID:
NCT02572895
Status:
UNKNOWN
Last Update Posted:
2016-09-09
First Post:
2015-10-08
Brief Title:
Cranberry Extract and Urinary Infection Prevention a Clinical Trial
Sponsor:
Laval University
Organization:
Laval University
Study Overview
Official Title:
Recurrent Urinary Tract Infection Prevention With Biologic Cranberry Extract Intake Standardized in Proanthocyanidins A Double-blind Clinical Trial
Status:
UNKNOWN
Status Verified Date:
2016-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PACCANN
Brief Summary:
The purpose of this clinical trial study is to assess among young and sexually active women presenting recurrent urinary tract infection UTIs efficacy of an optimal dose of cranberry extract quantified and standardized to 37 mgday of Proanthocyanidins PACs compared to a control dose quantified and standardized to 2 mgday of PACs on mean number of new UTIs during a 6-month follow-up period
Detailed Description:
Cranberry juice fruit fresh and dried functional foods and cranberry dietary supplements are promoted for prevention of urinary tract infections UTIs on the basis of their content of cranberry proanthocyanidins PACs with A-type interflavan bonds Several clinical trials have assessed efficacy of cranberry-derived products essentially with cranberry juices but discordant results have been found Lack of compliance but mostly lack of standardization in product concentrations can account for the variability among results Indeed most clinical trials do not report quantity of PACs According to most recent studies quantification of PACs requiring standardized and reproducible methods should be at least 37 mgday It can be hypothesized that efficacy of cranberry extract in UTIs prevention among young women can be strongly increased using optimal dosage standardized to 37 mgday of PACs The purpose of this clinical trial study is to assess among young and sexually active women presenting recurrent UTIs efficacy of an optimal dose of cranberry extract quantified and standardized to 37 mgday of PACs compared to a control dose quantified and standardized to 2 mgday of PACs on mean number of new UTIs during a 6-month follow-up period
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None